PharmaLogic to Acquire Lantheus' CDMO Business and Springfield, New Jersey Manufacturing Facility
Expands U.S. therapeutic manufacturing capacity and creates the first transatlantic CDMO platform with a proven commercial track record in radioligand therapies
WALTHAM, Mass., Nov. 9, 2026 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or the "Company"), the only independent contract development and manufacturing organization (CDMO) of scale dedicated exclusively to radiopharmaceuticals, today announced a definitive agreement to acquire the CDMO business and Springfield, New Jersey manufacturing facility from Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH). The financial terms of the transaction were not disclosed.
The Springfield facility is a state-of-the-art radiopharmaceutical manufacturing site with a proven track record in theranostic manufacturing, research and clinical development. Its highly skilled team will join Agilera, PharmaLogic's therapeutic CDMO franchise, upon completion of the transaction. The transaction also includes a long-term supply agreement under which Agilera will manufacture lutetium Lu 177 dotatate for Lantheus.
The acquisition expands PharmaLogic's capacity to manufacture radiopharmaceutical therapeutics in the U.S. Agilera brings more than 15 years of experience supporting the development and commercial launch of radioligand therapies (RLTs) and currently supplies an alpha therapy to more than 30 countries. With the Springfield facility, PharmaLogic becomes the first therapeutic CDMO to offer a transatlantic platform, giving partners an end-to-end solution for RLTs, from early clinical development through commercial launch and global supply.
"This acquisition strengthens Agilera's unique capabilities in radioligand therapies and expands our capacity in the U.S.," said Etienne Montagut, President and Chief Executive Officer of PharmaLogic. "We are proud to welcome the talented Springfield team, who will help us scale our operations to meet growing demand from our partners and the patients they serve."
"We have a long-standing relationship with PharmaLogic, which has been an important manufacturing partner for our PET products," said Mary Anne Heino, Executive Chairperson and Chief Executive Officer of Lantheus. "With its proven radiopharmaceutical expertise and manufacturing capabilities, PharmaLogic is the right long-term owner for the CDMO business and Springfield facility, with the capabilities to build on this foundation while supporting reliable supply of our newly approved radiotherapeutic for patients and healthcare providers."
The transaction is subject to applicable regulatory review and the satisfaction of other customary closing conditions. The parties will continue to operate independently until the closing.
Advisors
Leerink Partners served as financial advisor to the Company, and Goodwin Procter LLP served as legal advisor.
Solomon Partners Securities LLC served as financial advisor to Lantheus, and Covington & Burling LLP served as legal advisor.
About PharmaLogic Holdings Corp.
PharmaLogic is the only independent contract development and manufacturing organization (CDMO) of scale dedicated exclusively to radiopharmaceuticals in North America, serving both diagnostics and therapeutics. With decades of industry expertise and a robust network of more than 45 facilities across the U.S., Puerto Rico, Canada, and Norway, PharmaLogic delivers comprehensive solutions spanning development, manufacturing, and distribution of both clinical and commercial-stage radiopharmaceutical products, all in accordance with the highest quality and regulatory standards. Its integrated diagnostic and therapeutic capabilities allow PharmaLogic to support theranostic programs across the full product lifecycle, from first-in-human studies to long-term commercial supply.
Our rapidly expanding diagnostics business leverages advanced technologies to enhance patient access to novel diagnostics in oncology, cardiology, and neurology. In the therapeutic segment, PharmaLogic is the world's only cGMP-compliant CDMO currently manufacturing and distributing a commercial radiopharmaceutical therapeutic to more than 30 countries, with a strong track record of inspections by regulators in the U.S., Europe, China and other markets.
PharmaLogic is dedicated to enabling global patient access to radiopharmaceuticals through strategic development partnerships with industry innovators, advancing the future of the field and supporting our partners throughout the product lifecycle. For more information, visit pharmalogicgroup.com and follow us on LinkedIn.
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland, Sweden and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/pharmalogic-to-acquire-lantheus-cdmo-business-and-springfield-new-jersey-manufacturing-facility-302933626.html
This press release may not be republished, redistributed, resold or sublicensed without the prior written approval of PR Newswire.
AlphAI analysis
Written by AlphAI from the release above, not by the issuer or PR Newswire. Informational, not investment advice.
The 30-second read
Why it matters
The definitive agreement plus a long-term supply agreement for lutetium Lu 177 dotatate links the transaction directly to ongoing commercial supply needs, but the lack of financial terms and the regulatory closing overhang temper immediate valuation impact.
Market read
Traders may reprice both LNTH and PharmaLogic on deal execution, capacity expansion, and the implications of a long-term radiotherapeutic manufacturing supply arrangement.
What to watch
Execution risk around regulatory approvals, potential ramp constraints at the Springfield facility, and how the long-term supply agreement terms affect margins are not detailed.
Background
PharmaLogic is positioned as an independent radiopharmaceutical-focused CDMO, while Lantheus is a radiopharmaceutical company with PET and radiotherapeutic products.
Ticker impact
Lantheus agreed to sell its CDMO business and the Springfield, New Jersey radiopharmaceutical manufacturing facility to PharmaLogic under a definitive deal.
Shares may face uncertainty around deal economics and execution, partially offset by the long-term supply agreement for lutetium Lu 177 dotatate.
The article discloses a definitive agreement but provides no financial terms; it does include a long-term supply agreement tied to LNTH’s newly approved radiotherapeutic, which can reduce supply risk concerns.
Market effects
Strengthens competitive positioning in radioligand therapy CDMO capacity, potentially tightening supply and influencing partner outsourcing decisions.
Increases U.S. radiopharmaceutical manufacturing footprint via Springfield, New Jersey.
Creates a transatlantic CDMO platform, which may improve global supply reliability for radioligand therapies.
Counterpoint
Without disclosed financial terms, the market may discount the acquisition’s value and focus on integration and regulatory closing risk rather than capacity benefits.
Key entities
- companyPharmaLogic Holdings Corp.
Radiopharmaceutical-focused CDMO announcing acquisition of Lantheus’ CDMO business and Springfield, NJ facility.
- companyLantheus Holdings, Inc.
Radiopharmaceutical company selling its CDMO business and Springfield, NJ manufacturing facility to PharmaLogic.
- business_unitAgilera
PharmaLogic’s therapeutic CDMO franchise that will integrate the Springfield team and manufacture lutetium Lu 177 dotatate under a long-term supply agreement.